Do miRNAs Hold the Key to Controlling EBV-driven Tumorigenesis?

Silver, Benjamin; Krell, Jonathan; Frampton, Adam E.

doi:10.2217/fvl.12.97

Cited by 1 publication

(1 citation statement)

References 40 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EBV, also known as human herpesvirus 4 (HHV4), is a double-stranded DNA virus infecting over 90% of the adult population [13]. It was first discovered in 1964 by Tony Epstein and Yvonne Barr, when they used electron microscopy to identify herpesvirus-type particles in a subpopulation of Burkitt’s lymphoma (BL) cell lines from African patients [13]. Since then, EBV has been recognized as the first virus to be directly associated with human cancer.…”

Section: Ebv and Cancermentioning

confidence: 99%

Outlooks on Epstein-Barr virus associated gastric cancer

Naseem

Barzi

Brezden-Masley

et al. 2018

Cancer Treatment Reviews

167

143

View full text Add to dashboard Cite

Epstein-Barr virus associated gastric cancer (EBVaGC) comprises approximately 10% of gastric carcinomas. Multiple factors contribute to tumorigenesis, including EBV driven hypermethylation of tumor suppressor genes, inflammatory changes in gastric mucosa, host immune evasion by EBV and changes in cell cycle pathways. The unique molecular characteristics of EBVaGC, such as programmed death ligand 1 (PD-L1) overexpression, highlight the potential for using EBV as a biomarker for response to immunotherapy. Few studies have reported benefit from immunotherapy in EBV positive cancers, and clinical trials investigating the impact of checkpoint inhibitors in EBVaGC are currently underway. This review provides the most recent updates on molecular pathophysiology, epidemiology, clinical features and treatment advances pertaining to EBVaGC.

show abstract

Section: Ebv and Cancermentioning

confidence: 99%